Search research articles
Contact Us
Filters
Showing results (71-80 of 77) with videos related to
Page
of 8
Sort By:
You have reached the last page of results.
This site can display upto 77 results.
BMC Cancer
|
June 4, 2020
A phase II randomized trial of RAdium-223 dichloride and SABR Versus SABR for oligomEtastatic prostate caNcerS (RAVENS)
Hamza Hasan, Matthew P Deek, Ryan Phillips, et al.
European Urology Oncology
|
September 21, 2025
Genomic Predictors of Response to Metastasis-directed Therapy With or Without Androgen Deprivation Therapy
Philip Sutera, Kim Van der Eecken, Yang Song, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 11, 2022
Phase II Randomized Study of Salvage Radiation Therapy Plus Enzalutamide or Placebo for High-Risk Prostate-Specific Antigen Recurrent Prostate Cancer After Radical Prostatectomy: The SALV-ENZA Trial
Phuoc T Tran, Kathryn Lowe, Hua-Ling Tsai, et al.
European Urology
|
August 1, 2025
Continuous Androgen Deprivation Therapy with or Without Metastasis-directed Therapy for Oligometastatic Prostate Cancer: The Multicenter Phase 2 Randomized EXTEND Trial
Alexander D Sherry, Bilal A Siddiqui, Cara Haymaker, et al.
European Urology Oncology
|
April 19, 2024
Prognostic Significance of Immune Cell Infiltration in Muscle-invasive Bladder Cancer Treated with Definitive Chemoradiation: A Secondary Analysis of RTOG 0524 and RTOG 0712
Zaker Rana, Sophia C Kamran, Amol C Shetty, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 7, 2025
Outcomes of Radium-223 and Stereotactic Ablative Radiotherapy Versus Stereotactic Ablative Radiotherapy for Oligometastatic Prostate Cancers: The RAVENS Phase II Randomized Trial
Jarey H Wang, Alexander D Sherry, Soha Bazyar, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 24, 2022
Long-Term Outcomes and Genetic Predictors of Response to Metastasis-Directed Therapy Versus Observation in Oligometastatic Prostate Cancer: Analysis of STOMP and ORIOLE Trials
Matthew P Deek, Kim Van der Eecken, Philip Sutera, et al.
Page
of 8
Search research articles
Search
Showing results (71-80 of 77) with videos related to
Sort By:
Page
of 8
You have reached the last page of results.
This site can display upto 77 results.
BMC Cancer
|
June 4, 2020
A phase II randomized trial of RAdium-223 dichloride and SABR Versus SABR for oligomEtastatic prostate caNcerS (RAVENS)
Hamza Hasan, Matthew P Deek, Ryan Phillips, et al.
European Urology Oncology
|
September 21, 2025
Genomic Predictors of Response to Metastasis-directed Therapy With or Without Androgen Deprivation Therapy
Philip Sutera, Kim Van der Eecken, Yang Song, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 11, 2022
Phase II Randomized Study of Salvage Radiation Therapy Plus Enzalutamide or Placebo for High-Risk Prostate-Specific Antigen Recurrent Prostate Cancer After Radical Prostatectomy: The SALV-ENZA Trial
Phuoc T Tran, Kathryn Lowe, Hua-Ling Tsai, et al.
European Urology
|
August 1, 2025
Continuous Androgen Deprivation Therapy with or Without Metastasis-directed Therapy for Oligometastatic Prostate Cancer: The Multicenter Phase 2 Randomized EXTEND Trial
Alexander D Sherry, Bilal A Siddiqui, Cara Haymaker, et al.
European Urology Oncology
|
April 19, 2024
Prognostic Significance of Immune Cell Infiltration in Muscle-invasive Bladder Cancer Treated with Definitive Chemoradiation: A Secondary Analysis of RTOG 0524 and RTOG 0712
Zaker Rana, Sophia C Kamran, Amol C Shetty, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 7, 2025
Outcomes of Radium-223 and Stereotactic Ablative Radiotherapy Versus Stereotactic Ablative Radiotherapy for Oligometastatic Prostate Cancers: The RAVENS Phase II Randomized Trial
Jarey H Wang, Alexander D Sherry, Soha Bazyar, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 24, 2022
Long-Term Outcomes and Genetic Predictors of Response to Metastasis-Directed Therapy Versus Observation in Oligometastatic Prostate Cancer: Analysis of STOMP and ORIOLE Trials
Matthew P Deek, Kim Van der Eecken, Philip Sutera, et al.
Page
of 8